PULM - PulmatrixAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $1.58 | Open | $1.60 |
| Volume | 2.45M | Market Cap | 18.11M |
| Yield | Last Dividend |
| Pulmatrix Announces Commercial Launch of... | 10/21/20 |
| LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhal... | |
| Pulmatrix Announces Publication Demonstr... | 09/30/20 |
| LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ ??? Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inh... | |
| Pulmatrix Reports Q2 2020 Results and Bu... | 08/07/20 |
| LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhale... | |
| Pulmatrix Announces Progress by Sensory ... | 07/08/20 |
| LEXINGTON, Mass., July 8, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhale... | |
| Pulmatrix Announces Changes to Board of ... | 06/26/20 |
| LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhal... | |
| Pulmatrix to Host 2020 Annual Meeting of... | 05/27/20 |
| LEXINGTON, Mass., May 27, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhale... | |
| The Daily Biotech Pulse: Mixed Filgotini... | 05/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.)... | |
| Pulmatrix Reports Q1 2020 Results | 05/14/20 |
| LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhale... | |
| Pulmatrix : 4/A | MarketScreener | 05/14/20 |
| SEC Form 4 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5??? | May 14, 2020 | |
| Pulmatrix : DEF 14A | MarketScreener | 05/14/20 |
| Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??? | May 14, 2020 | |
| United States Long-Acting Bronchodilator... | 04/29/20 |
| DUBLIN--(BUSINESS WIRE)--The "US Long-Acting Bronchodilator Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The US long-... | |
| The Daily Biotech Pulse: Moderna Secures... | 04/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.) ... | |
| Pulmatrix Announces $8.0 Million Registe... | 04/16/20 |
| LEXINGTON, Mass., April 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inha... | |
| Pulmatrix and Sensory Cloud Announce Par... | 04/16/20 |
| LEXINGTON, Mass., April 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhal... | |
| Pulmatrix Receives Fast Track Designatio... | 01/30/20 |
| LEXINGTON, Mass., Jan. 30, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has gr... | |
| Pulmatrix Announces Research Collaborati... | 01/06/20 |
| LEXINGTON, Mass., Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhale... | |
| Pulmatrix Surges on License Agreement Wi... | 01/03/20 |
| Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung... | |
| Pulmatrix Shares Soar On Licensing Agree... | 01/02/20 |
| Pulmatrix Inc (NASDAQ: PULM ) announced a licensing agreement with Johnson & Johnson (NYSE: JNJ ) Monday, sending its shares sharply higher on above-a... | |
| HC Wainwright Reaffirms Buy Rating for P... | 11/14/19 |
| HC Wainwright reissued their buy rating on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Sunday, AnalystRatings.com repo... | |
| Pulmatrix appoints Life Sciences Executi... | 11/04/19 |
| LEXINGTON, Mass. , Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM ), a clinical stage biopharmaceutical company developing innovative inha... | |
| The Daily Biotech Pulse: Akebia Sues CMS... | 10/16/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) ... | |
| Pulmatrix misses by $0.15 | 05/15/19 |
| No summary available. | |
| CNET and BRS among premarket losers | 04/16/19 |
| No summary available. | |
| Pulmazole collaboration deal fails to li... | 04/15/19 |
| Pulmatrix ([[PULM]] -7.1%) is down on more than 60% higher volume on the heels of an agreement with Cipla Limited subsidiary Cipla Technologies to dev... | |
| WBA, EVOK and UGI among premarket losers | 04/02/19 |
| No summary available. | |
| Pulmatrix's stock rockets after deal wit... | 04/01/19 |
| Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet"??? | |
| CEL-SCI and Advaxis among healthcare gai... | 04/01/19 |
| No summary available. | |
| Pulmatrix up 59% on Pulmazole deal | 04/01/19 |
| No summary available. | |
| Cytokinetics and Fibrocell Science among... | 03/20/19 |
| No summary available. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
